Allosteric Targeting of the ACE2 Dimer Interface by a Medium-sized Compound Inhibits SARS-CoV-2 Entry
Open Access
- 22 June 2026
- journal article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (19) , 169914
Abstract
No abstract availableKeywords
Funding Information
- University of Tokyo
- Japan Agency for Medical Research and Development (JP21wm0325032)
- Japan Society for the Promotion of Science (JP24K02169)
- Japan Society for the Promotion of Science (JP21K06494)
- Takeda Science Foundation
This publication has 40 references indexed in Scilit:
- ACE2, a therapeutic target of COVID-19, needs to be treated with cautionArchives of Virology, 2025
- Global surveillance and countermeasures for ACE2-using MERS-related coronaviruses with spillover riskCell, 2025
- Prospects of Innovative Therapeutics in Combating the COVID-19 PandemicMolecular Biotechnology, 2024
- Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemicCell, 2023
- Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2Cell Discovery, 2022
- Advances in Targeting ACE2 for Developing COVID-19 TherapeuticsAnnals of Biomedical Engineering, 2022
- The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathioneBiochemical and Biophysical Research Communications, 2022
- NMR Based SARS-CoV-2 Antibody ScreeningJournal of the American Chemical Society, 2021
- Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2Cell Research, 2021
- Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface areaCurrent Opinion in Chemical Biology, 2018